Characteristics | Level | Alive n = 906 (91.8%) | Died n = 81 (8.2%) | p-value |
---|---|---|---|---|
District | Soroti | 418 (46.1) | 45 (55.6) | 0.027 |
Kumi | 213 (23.5) | 15 (18.5) | Â | |
Ngora | 125 (13.8) | 16 (19.8) | Â | |
Serere | 150 (16.6) | 5 (6.2) | Â | |
Level of health facility | Health Center IV | 386 (42.6) | 22 (27.2) | 0.023 |
District Hospital | 182 (20.1) | 19 (23.5) | Â | |
Referral Hospital | 338 (37.3) | 40 (49.4) | Â | |
Location of health facility | Rural | 252 (27.8) | 23 (28.4) | 1.000 |
Peri-urban | 654 (72.2) | 58 (71.6) | Â | |
Health facility ownership | Public | 808 (89.2) | 72 (88.9) | 1.000 |
Private not for profit | 98 (10.8) | 9 (11.1) | Â | |
Year of TB treatment | 2015 | 332 (36.6) | 35 (43.2) | 0.022 |
2016 | 192 (21.2) | 25 (30.9) | Â | |
2017 | 209 (23.1) | 14 (17.3) | Â | |
2018 | 173 (19.1) | 7 (8.6) | Â | |
Age category (years) | 15–34 | 436 (48.1) | 24 (29.6) | 0.002 |
35–50 | 297 (32.8) | 31 (38.3) |  | |
> 50 | 173 (19.1) | 26 (32.1) |  | |
Mean (SD) | 37.95 (15.05) | 44.80 (16.82) | < 0.001 | |
Sex | Male | 593 (65.5) | 58 (71.6) | 0.319 |
Female | 313 (34.5) | 23 (28.4) | Â | |
Persons with BC-PTB | New | 792 (87.4) | 70 (86.4) | 0.933 |
Previously treated | 114 (12.6) | 11 (13.6) | Â | |
Transfer in | No | 830 (91.6) | 73 (90.1) | 0.801 |
Yes | 76 (8.4) | 8 (9.9) | Â | |
Pre-therapy MTB load | 1+ | 130 (14.3) | 12 (14.8) | 0.948 |
2+ | 238 (26.3) | 20 (24.7) | Â | |
3+ | 287 (31.7) | 28 (34.6) | Â | |
GeneXpert | 251 (27.7) | 21 (25.9) | Â | |
Drug regimen | 2RHZE/4RH | 560 (61.8) | 41 (50.6) | 0.136 |
2RHZE/6HE | 280 (30.9) | 33 (40.7) | Â | |
2RHZES/1RHZE/5RHE | 66 (7.3) | 7 (8.6) | Â | |
HIV status | Negative | 673 (74.3) | 31 (38.3) | < 0.001 |
Positive | 233 (27.7) | 50 (61.7) | Â | |
Type of Directly Observed Therapy Short Course | Health facility | 36 (4.0) | 9 (11.1) | 0.008 |
Community | 870 (96.0) | 72 (88.9) | Â | |
Treatment support availability | No | 111 (12.3) | 11 (13.6) | 0.864 |
Yes | 795 (87.7) | 70 (86.4) | Â |